Previous 10 | Next 10 |
Sierra Oncology Presents Long-term Overall Survival and Sustained Efficacy Outcomes Data for Momelotinib at ASH Annual Meeting --Momelotinib demonstrates robust overall survival in both JAKi-naïve and patients previously treated with ruxolitinib-- VANCOUVER, BC ...
Sierra Oncology to Host KOL Panel Event to Discuss Updated Phase 3 Myelofibrosis Data Presented at ASH PR Newswire VANCOUVER, BC, Dec. 1, 2020 --Sierra Chief Development Officer Barbara Klencke to be joined by renowned myelofibrosis experts Jean-Jacques Kilad...
Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) PR Newswire VANCOUVER, BC, Nov. 25, 2020 VANCOUVER, BC, Nov. 25, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phas...
Sierra Oncology to Present at 2020 Jefferies Virtual London Healthcare Conference PR Newswire VANCOUVER, BC, Nov. 12, 2020 VANCOUVER, BC , Nov. 12, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3...
Sierra Oncology to Report Momelotinib Long-term Overall Survival Data in Oral Presentation at ASH 2020 PR Newswire VANCOUVER, BC, Nov. 5, 2020 - Efficacy data for momelotinib in myelofibrosis patients by baseline platelet levels also to be presented - VANCOUVER...
Sierra Oncology (SRRA): Q3 Non-GAAP EPS of -$1.19; GAAP EPS of -$1.39 beats by $0.23.Revenue of $0.1MPress Release For further details see: Sierra Oncology EPS beats by $0.23
Sierra Oncology Reports Third Quarter 2020 Results Canada NewsWire VANCOUVER, BC, Nov. 5, 2020 - MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 - VANCOUVER, BC, Nov. 5, 2020 /CNW/ - Sierra Oncology, Inc. (S...
Sierra Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire VANCOUVER, BC, Oct. 2, 2020 VANCOUVER, BC , Oct. 2, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the regist...
VANCOUVER, BC , Sept. 14, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor for the treatment of myelofibrosis, today announced that Dr. Stephen...
Sierra Oncology (NASDAQ: SRRA ) : Q2 Non-GAAP EPS of -$1.24; GAAP EPS of -$1.58 beats by $0.02 . More news on: Sierra Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submi...